Información del artículo
Resumen
Objetivo
En los últimos años se ha constatado un incremento en las infecciones causadas por cocos gram positivos en pacientes críticos, junto a un rápido desarrollo de resistencias a los antibióticos habitualmente empleados para su tratamiento. El objetivo es elaborar una guía de tratamiento antibiótico de las infecciones más frecuentes causadas por cocos gram positivos en pacientes críticos, que ayude a la toma de decisiones asistenciales.
MétodoExpertos de dos grupos de trabajo de dos sociedades científicas, pertenecientes al Grupo de estudio de Infecciones en el Paciente Crítico de la SEIMC (GEIPC-SEIMC) y al Grupo de Trabajo de Enfermedades Infecciosas de la SEMICYUC (GTEI-SEMICYUC), se reunieron con el objetivo de elaborar un documento de consenso. Se hizo una revisión sistemática de la literatura publicada hasta septiembre de 2006 referida a estas infecciones, y con los tratamientos antibióticos comercializados hasta entonces. Se aplicó un sistema de graduación de la evidencia según la fuerza de la recomendación (categorías A, B o C) y el grado de evidencia (categories I, II o III). Se realizaron las recomendaciones por consenso entre los expertos de ambas sociedades.
ResultadosSe presentan en forma de tablas las pautas antibióticas recomendadas para el tratamiento de las infecciones causadas por cocos gram positivos, reflejando el grado de recomendación. Se expresan las alternativas para el caso de pacientes alérgicos. En el texto se razona la base científica sobre la que se sustentan dichas recomendaciones citando las referencias en las que se apoyan.
ConclusionesSe presenta el resumen de una guía práctica, basada en la evidencia, para el tratamiento antibiótico de infecciones por cocos gram positivos en el paciente crítico.
Palabras clave:
Infecciones por cocos gram positivos
Pacientes críticos
Recomendaciones terapéuticas
Summary
Objective
In recent years there has been an increase in infections caused by gram-positive cocci in critical patients, together with a rapid development of resistance to the antibiotics which are normally used to treat them. The objective is to prepare an antibiotic treatment guide for the most common infections caused by gram positive cocci in critical patients. This guide will help in the decision-making process regarding the care of such patients.
MethodExperts from two scientific societies worked together to prepare a consensus document. They were members of the Study Group on Infections in Critical Patients (GEIPC), which is part of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC), and the Infectious Diseases Working Group (GTEI), belonging to the Spanish Society of Intensive Care Medicine and Coronary Units (SEMICYUC). There was a systematic review of the literature published up to September 2006 regarding this type of infections and the antibiotic treatments marketed to that date. An evidence grading system was applied according to the strength of the recommendation (categories A, B or C) and the level of evidence (categories I, II or III). Recommendations were given if there was consensus among the experts from both societies.
ResultsThe antibiotic regimens recommended for treating infections caused by gram-positive cocci were presented in the form of tables, showing the recommendation grade. Alternatives were given for allergic patients. The scientific basis supporting the aforementioned recommendations is explained within the text and the references upon which they are based are cited.
ConclusionsA summary of an evidence-based practical guide for the treatment of infections caused by gram-positive cocci in critical patients is presented.
Key words:
Infections caused by gram positive cocci
Critical patients
Therapeutic recommendations
El Texto completo está disponible en PDF
Bibliografía
[1.]
G.S. Martin, D.M. Mannino, S. Eaton, M. Moss.
The epidemiology of sepsis in the United States from 1979 through 2000.
N Engl J Med, 348 (2003), pp. 1546-1554
[2.]
F. Álvarez-Lerma, M. P.alomar, P. Olaechea, J.J. Otal, J. Insausti, E. Cerdá.
Estudio nacional de vigilancia de infección nosocomial en UCI. Informe evolutivo de los años 2003-2005.
Med Intensiva, 31 (2007), pp. 6-17
[3.]
National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 2004; 32: 470-85.
[4.]
P.M. Olaechea Astigarraga, M.J. Garnacho, C.S. Grau, C.O. Rodríguez, M.M. Palomar, C.R. Zaragoza, et al.
Recomendaciones de GEIPCSEIMC y GTEI-SEMICYUC para el tratamiento antibiótico de infecciones por cocos grampositivos en el paciente crítico.
Enferm Infecc Microbiol Clin, 25 (2007), pp. 446-466
[5.]
P.M. Olaechea Astigarraga, M.J. Garnacho, C.S. Grau, C.O. Rodríguez, M.M. Palomar, C.R. Zaragoza, et al.
Recomendaciones de GEIPCSEIMC y GTEI-SEMICYUC para el tratamiento antibiótico de infecciones por cocos grampositivos en el paciente crítico.
Med Intensiva, 31 (2007), pp. 294-317
[6.]
M.A. Kish.
Guide to development of practice guidelines.
Clin Infect Dis, 32 (2001), pp. 851-854
[7.]
H. Georges, O. Leroy, S. Alfandari, B. Guery, M. Roussel-Delvallez, C. Dhennain, et al.
Pulmonary disposition of vancomycin in critically ill patients.
Eur J Clin Microbiol Infect Dis, 16 (1997), pp. 385-388
[8.]
J.K. James, S.M. Palmer, D.P. Levine, M.J. Rybak.
Comparison of conventional dosing versus continuous-infusion vancomycin therapy for patients with suspected or documented gram-positive infections.
Antimicrob Agents Chemother, 40 (1996), pp. 696-700
[9.]
S. Blot.
MRSA pneumonia: Better outcome through continuous infusion of vancomycin?.
Crit Care Med, 33 (2005), pp. 2127-2128
[10.]
J. Rello, J. Sole-Violan, M. Sa-Borges, J. Garnacho-Montero, E. Muñoz, G. Sirgo, et al.
Pneumonia caused by oxacillin-resistant Staphylococcus aureus treated with glycopeptides.
Crit Care Med, 33 (2005), pp. 1983-1987
[11.]
S.K. Kasiakou, K.R. Lawrence, N. Choulis, M.E. Falagas.
Continuous versus intermittent intravenous administration of antibacterials with time-dependent action: A systematic review of pharmacokinetic and pharmacodynamic parameters.
Drugs, 65 (2005), pp. 2499-2511
[12.]
M. Wysocki, F. Delatour, F. Faurisson, A. Rauss, Y. Pean, B. Misset, et al.
Continuous versus intermittent infusion of vancomycin in severe Staphylococcal infections: Prospective multicenter randomized study.
Antimicrob Agents Chemother, 45 (2001), pp. 2460-2467
[13.]
Álvarez Lerma F. Neumonía relacionada con la ventilación mecánica. En: Estudio de Vigilancia de Infección nosocomial en UCI (ENVIN-UCI). Ed. Francisco Álvarez Lerma. Madrid: Jarpyo Editores S.A.; 2002. p. 53-72.
[14.]
J. Chastre, J.Y. Fagon.
Ventilator-associated pneumonia.
Am J Respir Crit Care Med, 165 (2002), pp. 867-903
[15.]
A. Torres, T.T. Bauer, C. León-Gil, F. Castillo, F. Álvarez-Lerma, A. Martínez-Pellus, et al.
Treatment of severe nosocomial pneumonia: A prospective randomised comparison of intravenous ciprofloxacin with imipenem/cilastatin.
Thorax, 55 (2000), pp. 1033-1039
[16.]
F. Álvarez-Lerma, J. Insausti-Ordeñana, R. Jordá-Marcos, E. Maravi-Poma, A. Torres-Martí, J. Nava, et al.
Efficacy and tolerability of piperacillin/tazobactam versus ceftazidime in association with amikacin for treating nosocomial pneumonia in intensive care patients: A prospective randomized multicenter trial.
Intensive Care Med, 27 (2001), pp. 493-502
[17.]
C. Brun-Buisson, J.P. Sollet, H. Schweich, S. Briere, C. Petit.
Treatment of ventilator-associated pneumonia with piperacillin-tazobactam/amikacin versus ceftazidime/amikacin: A multicenter, randomized controlled trial. VAP Study Group.
Clin Infect Dis, 26 (1998), pp. 346-354
[18.]
M. West, B.R. Boulanger, C. Fogarty, A. Tennenberg, B. Wiesinger, M. Oross, et al.
Levofloxacin compared with imipenem/cilastatin followed by ciprofloxacin in adult patients with nosocomial pneumonia: A multicenter, prospective, randomized, open-label study.
Clin Ther, 25 (2003), pp. 485-506
[19.]
B. Sieger, S.J. Berman, R.W. Geckler, S.A. Farkas.
Empiric treatment of hospital-acquired lower respiratory tract infections with meropenem or ceftazidime with tobramycin: A randomized study. Meropenem Lower Respiratory Infection Group.
Crit CareMed, 25 (1997), pp. 1663-1670
[20.]
D.L. Stevens, D. Herr, H. Lampiris, J.L. Hunt, D.H. Batts, B. Hafkin.
Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections.
Clin Infect Dis, 34 (2002), pp. 1481-1490
[21.]
R.G. Wunderink, J. Rello, S.K. Cammarata, R.V. Croos-Dabrera, M.H. Kollef.
Linezolid vs vancomycin: Analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia.
Chest, 124 (2003), pp. 1789-1797
[22.]
J. Fagon, H. Patrick, D.W. Haas, A. Torres, C. Gibert, W.G. Cheadle, et al.
Treatment of gram-positive nosocomial pneumonia. Prospective randomized comparison of quinupristin/dalfopristin versus vancomycin. Nosocomial Pneumonia Group.
Am J Respir Crit Care Med, 161 (2000), pp. 753-762
[23.]
C. González, M. Rubio, J. Romero-Vivas, M. González, J.J. Picazo.
Bacteremic pneumonia due to Staphylococcus aureus: A comparison of disease caused by methicillin-resistant and methicillin-susceptible organisms.
Clin Infect Dis, 29 (1999), pp. 1171-1177
[24.]
M.C. Birmingham, C.R. Rayner, A.K. Meagher, S.M. Flavin, D.H. Batts, J.J. Schentag.
Linezolid for the treatment of multidrug-resistant, gram-positive infections: Experience from a compassionate-use program.
Clin Infect Dis, 36 (2003), pp. 159-168
[25.]
Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005; 171: 388-416.
[26.]
J. Garnacho-Montero, C. Ortiz-Leyba, E. Fernández-Hinojosa, T. Aldabo-Pallas, A. Cayuela, J.A. Márquez-Vacaro, et al.
Acinetobacter baumannii ventilator-associated pneumonia: Epidemiological and clinical findings.
Intensive Care Med, 31 (2005), pp. 649-655
[27.]
A.F. Shorr, G.B. Susla, M.H. Kollef.
Quinolones for treatment of nosocomial pneumonia: A meta-analysis.
Clin Infect Dis, 40 (2005), pp. S115-S122
[28.]
A.F. Shorr, N. Zadeikis, W.L. Jackson, A.S. Ramage, S.C. Wu, A.M. Tennenberg, et al.
Levofloxacin for treatment of ventilator-associated pneumonia: A subgroup analysis from a randomized trial.
Clin Infect Dis, 40 (2005), pp. S123-S129
[29.]
G. Aubert, A. Carricajo, A.C. Vautrin, S. Guyomarch’, N. Fonsale, D. Page, et al.
Impact of restricting fluoroquinolone prescription on bacterial resistance in an intensive care unit.
J Hosp Infect, 59 (2005), pp. 83-89
[30.]
M.D. Kitzis, F.W. Goldstein.
Monitoring of vancomycin serum levels for the treatment of staphylococcal infections.
Clin Microbiol Infect, 12 (2006), pp. 92-95
[31.]
A. Combes, C.E. Luyt, J.Y. Fagon, M. Wollf, J.L. Trouillet, C. Gibert, et al.
Impact of methicillin resistance on outcome of Staphylococcus aureus ventilator-associated pneumonia.
Am J Respir Crit Care Med, 170 (2004), pp. 786-792
[32.]
O. Mimoz, D. Rolland, M. Adoun, S. Marchand, D. Breilh, I. Brumpt, et al.
Steady-state trough serum and epithelial lining fluid concentrations of teicoplanin 12 mg/kg per day in patients with ventilatorassociated pneumonia.
Intensive Care Med, 32 (2006), pp. 775-779
[33.]
E. Rubinstein, S. Cammarata, T. Oliphant, R. Wunderink.
Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: A randomized, double-blind, multicenter study.
Clin Infect Dis, 32 (2001), pp. 402-412
[34.]
R.G. Wunderink, S.K. Cammarata, T.H. Oliphant, M.H. Kollef.
Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia.
Clin Ther, 25 (2003), pp. 980-992
[35.]
M.H. Kollef, J. Rello, S.K. Cammarata, R.V. Croos-Dabrera, R.G. Wunderink.
Clinical cure and survival in Gram-positive ventilator-associated pneumonia: Retrospective analysis of two double-blind studies comparing linezolid with vancomycin.
Intensive Care Med, 30 (2004), pp. 388-394
[36.]
J.E. Conte Jr, J.A. Golden, J. Kipps, E. Zurlinden.
Intrapulmonary pharmacokinetics of linezolid.
Antimicrob Agents Chemother, 46 (2002), pp. 1475-1480
[37.]
E. Boselli, D. Breilh, T. Rimmele, S. Djabarouti, J. Toutain, D. Chassard, et al.
Pharmacokinetics and intrapulmonary concentrations of linezolid administered to critically ill patients with ventilator-associated pneumonia.
Crit Care Med, 33 (2005), pp. 1529-1533
[38.]
C.G. Gemmell, D.I. Edwards, A.P. Fraise, F.K. Gould, G.L. Ridgway, R.E. Warren.
Guidelines for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the UK.
J Antimicrob Chemother, 57 (2006), pp. 589-608
[39.]
F. Álvarez-Lerma, S. Grau, M.P. Gracía-Arnillas.
Gram-positive cocci infections in intensive care: Guide to antibacterial selection.
Drugs, 66 (2006), pp. 751-768
[40.]
G. Sakoulas, P.A. Moise-Broder, J. Schentag, A. Forrest, R.C. Moellering Jr, G.M. Eliopoulos.
Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia.
J Clin Microbiol, 42 (2004), pp. 2398-2402
[41.]
O. Cuevas, E. Cercenado, A. Vindel, J. Guinea, M. Sánchez-Conde, M. Sánchez-Somolinos, et al.
Evolution of the antimicrobial resistance of Staphylococcus spp. in Spain: Five nationwide prevalence studies, 1986 to 2002.
Antimicrob Agents Chemother, 48 (2004), pp. 4240-4245
[42.]
J. Oteo, F. Baquero, A. Vindel, J. Campos.
Antibiotic resistance in 3,113 blood isolates of Staphylococcus aureus in 40 Spanish hospitals participating in the European Antimicrobial Resistance Surveillance System (2000-2002).
J Antimicrob Chemother, 53 (2004), pp. 1033-1038
[43.]
M. Domínguez, C. Borraz, M. González, J. Rodríguez Baño, R. Martín, B. Almirante, et al.
Molecular characterization of methicillin-resistant Staphylococcus aureus (MRSA) isolated in a Spanish multicenter study.
45th Insterscience Conference of Antimicrobial Agents and Chemotherapy,
[44.]
A.C. Fluit, C.L. Wielders, J. Verhoef, F.J. Schmitz.
Epidemiology and susceptibility of 3,051 Staphylococcus aureus isolates from 25 university hospitals participating in the European SENTRY study.
J Clin Microbiol, 39 (2001), pp. 3727-3732
[45.]
J. Chastre, M. Wolff, J.Y. Fagon, S. Chevret, F. Thomas, D. Wermert, et al.
Comparison of 8 vs. 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: A randomized trial.
JAMA, 290 (2003), pp. 2588-2598
[46.]
P.M. Houck, D.W. Bratzler, W. Nsa, A. Ma, J.G. Bartlett.
Timing of antibiotic administration and outcomes for Medicare patients hospitalized with community-acquired pneumonia.
Arch Intern Med, 164 (2004), pp. 637-644
[47.]
L.A. Mandell, J.G. Bartlett, S.F. Dowell, T.M. File Jr, D.M. Musher, C. Whitney.
Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults.
Clin Infect Dis, 37 (2003), pp. 1405-1433
[48.]
BTS.
Guidelines for the Management of Community Acquired Pneumonia in Adults.
Thorax, 56 (2001), pp. IV1-IV64
[49.]
T.M. File, J. Garau, M.R. Jacobs, B. Wynne, M. Twynholm, E. Berkowitz.
Efficacy of a new pharmacokinetically enhanced formulation of amoxicillin/clavulanate (2000/125 mg) in adults with communityacquired pneumonia caused by Streptococcus pneumoniae, including penicillin-resistant strains.
Int J Antimicrob Agents, 25 (2005), pp. 110-119
[50.]
G.W. Waterer, G.W. Somes, R.G. Wunderink.
Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia.
Arch Intern Med, 161 (2001), pp. 1837-1842
[51.]
J.A. Martínez, J.P. Horcajada, M. Almela, F. Marco, A. Soriano, E. García, et al.
Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia.
Clin Infect Dis, 36 (2003), pp. 389-395
[52.]
L.M. Baddour, V.L. Yu, K.P. Klugman, C. Feldman, A. Ortqvist, J. Rello, et al.
Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia.
Am J Respir Crit Care Med, 170 (2004), pp. 440-444
[53.]
S. Harbarth, J. Garbino, J. Pugin, J.A. Romand, D. Pittet.
Lack of effect of combination antibiotic therapy on mortality in patients with pneumococcal sepsis.
Eur J Clin Microbiol Infect Dis, 24 (2005), pp. 688-690
[54.]
G.W. Waterer.
Optimal antibiotic treatment in severe pneumococcal pneumonia-time for real answers.
Eur J Clin Microbiol Infect Dis, 24 (2005), pp. 691-692
[55.]
J. Oteo, J. Campos, S. Cruchaga, G. Baquero, E. Lázaro, M. Madurga, et al.
Increase of resistance to macrolides in invasive Streptococcus pneumoniae in Spain (2000-2001).
ClinMicrobiol Infect, 10 (2004), pp. 851-854
[56.]
E. Pérez-Trallero, C. García-de-la-Fuente, C. García-Rey, F. Baquero, L. Aguilar, R. Dal Re, et al.
Geographical and ecological analysis of resistance, coresistance, and coupled resistance to antimicrobials in respiratory pathogenic bacteria in Spain.
Antimicrob Agents Chemother, 49 (2005), pp. 1965-1972
[57.]
E.M. Mortensen, M.I. Restrepo, A. Anzueto, J. Pugh.
The impact of empiric antimicrobial therapy with a beta-lactam and fluoroquinolone on mortality for patients hospitalized with severe pneumonia.
Crit Care, 10 (2005), pp. R8
[58.]
O. Leroy, P. Saux, J.P. Bedos, E. Caulin.
Comparison of levofloxacin and cefotaxime combined with ofloxacin for ICU patients with community-acquired pneumonia who do not require vasopressors.
Chest, 128 (2005), pp. 172-183
[59.]
V.L. Yu, C.C. Chiou, C. Feldman, A. Ortqvist, J. Rello, A.J. Morris, et al.
An international prospective study of pneumococcal bacteremia: Correlation with in vitro resistance, antibiotics administered, and clinical outcome.
Clin Infect Dis, 37 (2003), pp. 230-237
[60.]
L.R. Peterson.
Penicillins for treatment of pneumococcal pneumonia: Does in vitro resistance really matter?.
Clin Infect Dis, 42 (2006), pp. 224-233
[61.]
M. Luján, M. Gallego, D. Fontanals, D. Mariscal, J. Rello.
Prospective observational study of bacteremic pneumococcal pneumonia: Effect of discordant therapy on mortality.
Crit Care Med, 32 (2004), pp. 625-631
[62.]
G.S. San Pedro, S.K. Cammarata, T.H. Oliphant, T. Todisco.
Linezolid versus ceftriaxone/cefpodoxime in patients hospitalized for the treatment of Streptococcus pneumoniae pneumonia.
Scand J Infect Dis, 34 (2002), pp. 720-728
[63.]
G. Ortiz-Ruiz, N. Vetter, R. Isaacs, A. Carides, G.L. Woods, I. Friedland.
Ertapenem versus ceftriaxone for the treatment of communityacquired pneumonia in adults: Combined analysis of two multicentre randomized, double-blind studies.
J Antimicrob Chemother, 53 (2004), pp. ii59-ii66
[64.]
L.A. Mandell, T.M. File Jr.
Short-course treatment of communityacquired pneumonia.
Clin Infect Dis, 37 (2003), pp. 761-763
[65.]
M.J. Richards, J.R. Edwards, D.H. Culver, R.P. Gaynes.
Nosocomial infections in combined medical-surgical intensive care units in the United States.
Infect Control Hosp Epidemiol, 21 (2000), pp. 510-515
[66.]
P. Olaechea, F. Álvarez-Lerma, M. Palomar, J. Insausti, E. Cerdá, A. Arenzana, Grupo de Estudio Nacional de Vigilancia de Infección Nosocomial en UCI (ENVIN-UCI), et al.
Evolución de las tasas y etiología de la bacteriemia primaria y relacionada con catéter en pacientes críticos. Estudio ENVIN-UCI 1997-2005.
Enferm Infecc Microbiol Clin, 24 (2006), pp. 107-108
[67.]
L.A. Mermel, B.M. Farr, R.J. Sherertz, I.I. Raad, N. O’Grady, J.S. Harris, et al.
Guidelines for the management of intravascular catheter-related infections.
J Intraven Nurs, 24 (2001), pp. 180-205
[68.]
J. Ariza, C. León, A. Rodríguez Noriega, E. Fernández Mondéjar.
Conclusiones de la conferencia de consenso en infecciones por catéter.
Med Intensiva, 27 (2003), pp. 615-620
[69.]
A.F. Shorr, M.J. Kunkel, M. Kollef.
Linezolid versus vancomycin for Staphylococcus aureus bacteraemia: Pooled analysis of randomized studies.
J Antimicrob Chemother, 56 (2005), pp. 923-929
[70.]
J.A. Cepeda, T. Whitehouse, B. Cooper, J. Hails, K. Jones, F. Kwaku, et al.
Linezolid versus teicoplanin in the treatment of Gram-positive infections in the critically ill: A randomized, double-blind, multicentre study.
J Antimicrob Chemother, 53 (2004), pp. 345-355
[71.]
M. Wilcox, D. Nathwani, M. Dryden.
Linezolid compared with teicoplanin for the treatment of suspected or proven Gram-positive infections.
J Antimicrob Chemother, 53 (2004), pp. 335-344
[72.]
M. Herrmann, G. Peters.
Catheter-associated infections caused by coagulase-negative staphylococci: Clinical and biological aspects.
Catheter-related infections, pp. 79-109
[73.]
F.Y. Chang, J.E. Peacock Jr, D.M. Musher, P. Triplett, B.B. MacDonald, J.M. Mylotte, et al.
Staphylococcus aureus bacteremia: Recurrence and the impact of antibiotic treatment in a prospective multicenter study.
Medicine (Baltimore), 82 (2003), pp. 333-339
[74.]
R. Khatib, S. Saeed, M. Sharma, K. Riederer, M.G. Fakih, L.B. Johnson.
Impact of initial antibiotic choice and delayed appropriate treatment on the outcome of Staphylococcus aureus bacteremia.
Eur J Clin Microbiol Infect Dis, 25 (2006), pp. 181-185
[75.]
S.I. Blot, K.H. Vandewoude, E.A. Hoste, F.A. Colardyn.
Outcome and attributable mortality in critically Ill patients with bacteremia involving methicillin-susceptible and methicillin-resistant Staphylococcus aureus.
Arch Intern Med, 162 (2002), pp. 2229-2235
[76.]
R.K. Gang, S.C. Sanyal, E. Mokaddas, A.R. Lari.
Rifampicin as an adjunct to vancomycin therapy in MRSA septicaemia in burns.
Burns, 25 (1999), pp. 640-644
[77.]
B.P. Howden, P.B. Ward, P.G. Charles, T.M. Korman, A. Fuller, C.P. Du, et al.
Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility.
Clin Infect Dis, 38 (2004), pp. 521-528
[78.]
C. Watanakunakorn, R. Patel.
Comparison of patients with enterococcal bacteremia due to strains with and without high-level resistance to gentamicin.
Clin Infect Dis, 17 (1993), pp. 74-78
[79.]
J.E. Patterson, A.H. Sweeney, M. Simms, N. Carley, R. Mangi, J. Sabetta, et al.
An analysis of 110 serious enterococcal infections. Epidemiology, antibiotic susceptibility, and outcome.
Medicine (Baltimore), 74 (1995), pp. 191-200
[80.]
J.A. Sandoe, I.R. Witherden, H.K. Au-Yeung, P. Kite, K.G. Kerr, M.H. Wilcox.
Enterococcal intravascular catheter-related bloodstream infection: Management and outcome of 61 consecutive cases.
J Antimicrob Chemother, 50 (2002), pp. 577-582
[81.]
B.E. Murray.
Vancomycin-resistant enterococcal infections.
N Engl J Med, 342 (2000), pp. 710-721
[82.]
S.H. Kim, W.B. Park, K.D. Lee, C.I. Kang, H.B. Kim, M.D. Oh, et al.
Outcome of Staphylococcus aureus bacteremia in patients with eradicable foci versus noneradicable foci.
Clin Infect Dis, 37 (2003), pp. 794-799
[83.]
J.M. Flores-Cordero, R. Amaya-Villar, M.D. Rincón-Ferrari, S.R. Leal-Noval, J. Garnacho-Montero, A.C. Llanos-Rodríguez, et al.
Acute community-acquired bacterial meningitis in adults admitted to the intensive care unit: Clinical manifestations, management and prognostic factors.
Intensive Care Med, 29 (2003), pp. 1967-1973
[84.]
M.L. Durand, S.B. Calderwood, D.J. Weber, S.I. Miller, F.S. Southwick, V.S. Caviness Jr, et al.
Acute bacterial meningitis in adults. A review of 493 episodes.
N Engl J Med, 328 (1993), pp. 21-28
[85.]
V. Pintado, M.A. Meseguer, J. Fortún, J. Cobo, E. Navas, C. Quereda, et al.
Clinical study of 44 cases of Staphylococcus aureus meningitis.
Eur J Clin Microbiol Infect Dis, 21 (2002), pp. 864-868
[86.]
A.R. Tunkel, B.J. Hartman, S.L. Kaplan, B.A. Kaufman, K.L. Roos, W.M. Scheld, et al.
Practice guidelines for the management of bacterial meningitis.
Clin Infect Dis, 39 (2004), pp. 1267-1284
[87.]
B.D. van de, J. de Gans, A.R. Tunkel, E.F. Wijdicks.
Community-acquired bacterial meningitis in adults.
N Engl J Med, 354 (2006), pp. 44-53
[88.]
S. Ribes, F. Taberner, A. Domenech, C. Cabellos, F. Tubau, J. Linares, et al.
Evaluation of ceftriaxone, vancomycin and rifampicin alone and combined in an experimental model of meningitis caused by highly cephalosporin-resistant Streptococcus pneumoniae ATCC 51916.
J Antimicrob Chemother, 56 (2005), pp. 979-982
[89.]
C.M. Gerber, M. Cottagnoud, K.A. Neftel, M.G. Tauber, P. Cottagnoud.
Meropenem alone and in combination with vancomycin in experimental meningitis caused by a penicillin-resistant pneumococcal strain.
Eur J Clin Microbiol Infect Dis, 18 (1999), pp. 866-870
[90.]
J. Martínez-Lacasa, C. Cabellos, A. Martos, A. Fernández, F. Tubau, P.F. Viladrich, et al.
Experimental study of the efficacy of vancomycin, rifampicin and dexamethasone in the therapy of pneumococcal meningitis.
J Antimicrob Chemother, 49 (2002), pp. 507-513
[91.]
C. Carbon.
Comparison of side effects of levofloxacin versus other fluoroquinolones.
Chemother, 47 (2001), pp. 9-14
[92.]
D.E. Laguna, M.R. Salgado, S.S. Calabrese, A.J. Murillas, A.E. Martín, M.S. Moya Mir.
Meningitis bacteriana del adulto: análisis clínico y de desarrollo de 100 casos.
An Med Interna, 13 (1996), pp. 520-526
[93.]
J. Elvira, D.R. García, J. Chamorro, S.A. López, I. Tinoco, M.C. Rodríguez Leal, et al.
Estudio prospectivo de las meningitis diagnosticadas en un hospital de tercer nivel durante un periodo de un año.
Rev Clin Esp, 199 (1999), pp. 576-582
[94.]
M. Weisfelt, J. de Gans, P.T. van der, B.D. van de.
Pneumococcal meningitis in adults: New approaches to management and prevention.
Lancet Neurol, 5 (2006), pp. 332-342
[95.]
J.J. Lewin, M. Lapointe, W.C. Ziaia.
Central nervous system infections in the critically ill.
J Pharm Practs, 18 (2005), pp. 25-41
[96.]
J. Albanese, M. Leone, B. Bruguerolle, M.L. Ayem, B. Lacarelle, C. Martin.
Cerebrospinal fluid penetration and pharmacokinetics of vancomycin administered by continuous infusion to mechanically ventilated patients in an intensive care unit.
Antimicrob Agents Chemother, 44 (2000), pp. 1356-1358
[97.]
P. Cottagnoud, C.M. Gerber, F. Acosta, M. Cottagnoud, K. Neftel, M.G. Tauber.
Linezolid against penicillin-sensitive and resistant pneumococci in the rabbit meningitis model.
J Antimicrob Chemother, 46 (2000), pp. 981-985
[98.]
F. Faella, P. Pagliano, U. Fusco, V. Attanasio, M. Conte.
Combined treatment with ceftriaxone and linezolid of pneumococcal meningitis: A case series including penicillin-resistant strains.
Clin Microbiol Infect, 12 (2006), pp. 391-394
[99.]
E. Schmutzhard, K.J. Williams, G. Vukmirovits, V. Chmelik, B. Pfausler, A. Featherstone.
A randomised comparison of meropenem with cefotaxime or ceftriaxone for the treatment of bacterial meningitis in adults. Meropenem Meningitis Study Group.
J Antimicrob Chemo, 36 (1995), pp. 85-97
[100.]
S.W. Kim, J.H. Jin, S.J. Kang, S.I. Jung, Y.S. Kim, C.K. Kim, et al.
Therapeutic efficacy of meropenem for treatment of experimental penicillin-resistant pneumococcal meningitis.
J Korean Med Sci, 19 (2004), pp. 21-26
[101.]
P. Viale, L. Pagani, F. Cristini, R. Stefini, R. Bergomi, P. Colombini, et al.
Linezolid for the treatment of central nervous system infections in neurosurgical patients.
Scand J Infect Dis, 34 (2002), pp. 456-459
[102.]
T.A. Rupprecht, H.W. Pfister.
Clinical experience with linezolid for the treatment of central nervous system infections.
Eur J Neurol, 12 (2005), pp. 536-542
[103.]
A.M. Korinek.
Risk factors for neurosurgical site infections after craniotomy: A prospective multicenter study of 2,944 patients. The French Study Group of Neurosurgical Infections, the SEHP, and the C-CLIN Paris-Nord. Service Epidemiologie Hygiene et Prevention.
Neurosurg, 41 (1997), pp. 1073-1079
[104.]
B. Pfausler, H. Spiss, R. Beer, A. Kampl, K. Engelhardt, M. Schober, et al.
Treatment of staphylococcal ventriculitis associated with external cerebrospinal fluid drains: A prospective randomized trial of intravenous compared with intraventricular vancomycin therapy.
J Neurosurg, 98 (2003), pp. 1040-1044
[105.]
W.A. Krueger, B. Kottler, B.E. Will, A. Heininger, H. Guggenberger, K.E. Unertl.
Treatment of meningitis due to methicillin-resistant Staphylococcus epidermidis with linezolid.
J Clin Microbiol, 42 (2004), pp. 929-932
[106.]
M.P. Lalueza Broto, M.R. López, C.L. Domínguez, V. Garnacho.
Tratamiento con linezolid en la meningitis por Staphylococcus epidermidis multirresistente.
Med Clin (Barc), 122 (2004), pp. 238-239
[107.]
V. Pintado, C. Cabellos, S. Moreno, M.A. Meseguer, J. Ayats, P.F. Viladrich.
Enterococcal meningitis: A clinical study of 39 cases and review of the literature.
Medicine (Baltimore), 82 (2003), pp. 346-364
[108.]
H.S. Gold.
Vancomycin-resistant enterococci: Mechanisms and clinical observations.
Clin Infect Dis, 33 (2001), pp. 210-219
[109.]
C. Zeana, C.J. Kubin, P. Della-Latta, S.M. Hammer.
Vancomycin-resistant Enterococcus faecium meningitis successfully managed with linezolid: Case report and review of the literature.
Clin Infect Dis, 33 (2001), pp. 477-482
[110.]
S. Sabbatani, R. Manfredi, G. Frank, F. Chiodo.
Linezolid in the treatment of severe central nervous system infections resistant to recommended antimicrobial compounds.
Infez Med, 13 (2005), pp. 112-119
[111.]
P. Montravers, R. Gauzit, C. Muller, J.P. Marmuse, A. Fichelle, J.M. Desmonts.
Emergence of antibiotic-resistant bacteria in cases of peritonitis after intraabdominal surgery affects the efficacy of empirical antimicrobial therapy.
Clin Infect Dis, 23 (1996), pp. 486-494
[112.]
A. Sitges-Serra, M.J. López, M. Girvent, S. Almirall, J.J. Sancho.
Postoperative enterococcal infection after treatment of complicated intraabdominal sepsis.
Br J Surg, 89 (2002), pp. 361-367
[113.]
O. Gajic, L.E. Urrutia, H. Sewani, D.R. Schroeder, D.C. Cullinane, S.G. Peters.
Acute abdomen in the medical intensive care unit.
Crit Care Med, 30 (2002), pp. 1187-1190
[114.]
P.F. Wong, A.D. Gilliam, S. Kumar, J. Shenfine, G.N. O’Dair, D.J. Leaper.
Antibiotic regimens for secondary peritonitis of gastrointestinal origin in adults.
Cochrane Database Syst Rev, (2005),
[115.]
J.S. Solomkin, J.E. Mazuski, E.J. Baron, R.G. Sawyer, A.B. Nathens, J.T. DiPiro, et al.
Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections.
Clin Infect Dis, 37 (2003), pp. 997-1005
[116.]
Oliva ME, Rekha A, Yellin A, Pasternak J, Campos M, Rose GM, et al. A multicenter trial of the efficacy and safety of tigecycline versus imipenem/cilastatin in patients with complicated intra-abdominal infections [Study ID Numbers: 3074A1-301-WW; ClinicalTrials.gov Identifier: NCT00081744]. BMC Infect Dis 2005; 5: 88.
[117.]
J.S. Solomkin, A.E. Yellin, O.D. Rotstein, N.V. Christou, E.P. Dellinger, J.M. Tellado, et al.
Ertapenem versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections: Results of a double-blind, randomized comparative phase III trial.
Ann Surg, 237 (2003), pp. 235-245
[118.]
J.M. Tellado, A. Sitges-Serra, F. Barcenilla, M. Palomar, R. Serrano, J. Barberán, et al.
Pautas de tratamiento antibiótico empírico de las infecciones intraabdominales.
Rev Esp Quimioter, 18 (2005), pp. 179-186
[119.]
K.B. Laupland, S.M. Bagshaw, D.B. Gregson, A.W. Kirkpatrick, T. Ross, D.L. Church.
Intensive care unit-acquired urinary tract infections in a regional critical care system.
Crit Care (Revista electrónica), 9 (2005), pp. R60-R65
[120.]
P. Olaechea, F. Álvarez-Lerma, M. Palomar, J. Insausti, E. Cerdá, A. Raya, Grupo de Estudio Nacional de Vigilancia de Infección Nosocomial en UC (ENVIN-UCI), et al.
Evolución de las tasas y etiología de las infecciones urinarias relacionadas con sondaje uretral en pacientes críticos. Estudio ENVIN-UCI 1994-2005.
Enferm Infecc Microbiol Clin, 24 (2006), pp. 14-19
[121.]
W.G. Wells, G.L. Woods, Q. Jiang, R.M. Gesser.
Treatment of complicated urinary tract infection in adults: Combined analysis of two randomized, double-blind, multicentre trials comparing ertapenem and ceftriaxone followed by appropriate oral therapy.
J Antmicrob Chemother, 53 (2004), pp. ii67-ii74
[122.]
R.R. Muder, C. Brennen, J.D. Rihs, M.M. Wagener, A. Obman, J.E. Stout, et al.
Isolation of Staphylococcus aureus from the urinary tract: Association of isolation with symptomatic urinary tract infection and subsequent staphylococcal bacteremia.
Clin Infect Dis, 42 (2006), pp. 46-50
[123.]
E. Bouza, A. Menasalvas, P. Muñoz, F.J. Vasallo, M.M. del Mar, M.A. García Fernández.
Infective endocarditis-a prospective study at the end of the twentieth century: New predisposing conditions, new etiologic agents, and still a high mortality.
Medicine (Baltimore), 80 (2001), pp. 298-307
[124.]
V.G. Fowler Jr, J.M. Miro, B. Hoen, C.H. Cabell, E. Abrutyn, E. Rubinstein, et al.
Staphylococcus aureus endocarditis: A consequence of medical progress.
JAMA, 293 (2005), pp. 3012-3021
[125.]
L.M. Baddour, W.R. Wilson, A.S. Bayer, V.G. Fowler Jr, A.F. Bolger, M.E. Levison, Infective endocarditis: Diagnosis, antimicrobial therapy, and management of complications: A statement for healthcare professionals from the Committee, et al.
on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: Endorsed by the Infectious Diseases Society of America.
Circulation, 111 (2005), pp. e394-e434
[126.]
P. Francioli, J. Etienne, R. Hoigne, J.P. Thys, A. Gerber.
Treatment of streptococcal endocarditis with a single daily dose of ceftriaxone sodium for 4 weeks. Efficacy and outpatient treatment feasibility.
JAMA, 267 (1992), pp. 264-267
[127.]
P. Francioli, W. Ruch, D. Stamboulian.
Treatment of streptococcal endocarditis with a single daily dose of ceftriaxone and netilmicin for 14 days: A prospective multicenter study.
Clin Infect Dis, 21 (1995), pp. 1406-1410
[128.]
D.J. Sexton, M.J. Tenenbaum, W.R. Wilson, J.M. Steckelberg, A.D. Tice, D. Gilbert, et al.
Ceftriaxone once daily for four weeks compared with ceftriaxone plus gentamicin once daily for two weeks for treatment of endocarditis due to penicillin-susceptible streptococci. Endocarditis Treatment Consortium Group.
Clin Infect Dis, 27 (1998), pp. 1470-1474
[129.]
E. Martínez, J.M. Miró, B. Almirante, J.M. Aguado, P. Fernández-Viladrich, M.L. Fernández-Guerrero, et al.
Effect of penicillin resistance of Streptococcus pneumoniae on the presentation, prognosis, and treatment of pneumococcal endocarditis in adults.
Clin Infect Dis, 35 (2002), pp. 130-139
[130.]
P. Muñoz, J. Sainz, M. Rodríguez-Creixems, J. Santos, L. Alcalá, E. Bouza.
Austrian syndrome caused by highly penicillin-resistant Streptococcus pneumoniae.
Clin Infect Dis, 29 (1999), pp. 1591-1592
[131.]
A. Lefort, J.L. Mainardi, C. Selton-Suty, P. Casassus, L. Guillevin, O. Lortholary.
Streptococcus pneumoniae endocarditis in adults. A multicenter study in France in the era of penicillin resistance (1991-1998). The Pneumococcal Endocarditis Study Group.
Medicine (Baltimore), 79 (2000), pp. 327-337
[132.]
S.I. Aronin, S.K. Mukherjee, J.C. West, E.L. Cooney.
Review of pneumococcal endocarditis in adults in the penicillin era.
Clin Infect Dis, 26 (1998), pp. 165-171
[133.]
M. Siegel, J. Timpone.
Penicillin-resistant Streptococcus pneumoniae endocarditis: A case report and review.
Clin Infect Dis, 32 (2001), pp. 972-974
[134.]
M.J. DiNubile.
Short-course antibiotic therapy for right-sided endocarditis caused by Staphylococcus aureus in injection drug users.
Ann Intern Med, 121 (1994), pp. 873-876
[135.]
A.W. Heldman, T.V. Hartert, S.C. Ray, E.G. Daoud, T.E. Kowalski, V.J. Pompili, et al.
Oral antibiotic treatment of right-sided staphylococcal endocarditis in injection drug users: Prospective randomized comparison with parenteral therapy.
Am J Med, 101 (1996), pp. 68-76
[136.]
J. Fortun, J.A. Pérez-Molina, M.T. Anon, J. Martínez-Beltrán, E. Loza, A. Guerrero.
Right-sided endocarditis caused by Staphylococcus aureus in drug abusers.
Antimicrob Agents Chemother, 39 (1995), pp. 525-528
[137.]
M. Torres-Tortosa, M. de Cueto, A. Vergara, A. Sánchez-Porto, E. Pérez-Guzmán, M. González-Serrano, et al.
Prospective evaluation of a two-week course of intravenous antibiotics in intravenous drug addicts with infective endocarditis.
Eur J Clin Microbiol Infect Dis, 13 (1994), pp. 559-564
[138.]
H.F. Chambers.
Short-course combination and oral therapies of Staphylococcus aureus endocarditis.
Infect Dis Clin North Am, 7 (1993), pp. 69-80
[139.]
E. Ribera, J. Gómez-Jiménez, E. Cortés, O. del Valle, A. Planes, T. González-Alujas, et al.
Effectiveness of cloxacillin with and without gentamicin in short-term therapy for right-sided Staphylococcus aureus endocarditis. A randomized, controlled trial.
Ann Intern Med, 125 (1996), pp. 969-974
[140.]
P. Dodek, P. Phillips.
Questionable history of immediate-type hypersensitivity to penicillin in Staphylococcal endocarditis: Treatment based on skin-test results versus empirical alternative treatment –A decision analysis.
Clin Infect Dis, 29 (1999), pp. 1251-1256
[141.]
D.P. Levine, B.S. Fromm, B.R. Reddy.
Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis.
Ann Intern Med, 115 (1991), pp. 674-680
[142.]
N. Markowitz, E.L. Quinn, L.D. Saravolatz.
Trimethoprim-sulfamethoxazole compared with vancomycin for the treatment of Staphylococcus aureus infection.
Ann Intern Med, 117 (1992), pp. 390-398
[143.]
M.D. John, P.L. Hibberd, A.W. Karchmer, L.A. Sleeper, S.B. Calderwood.
Staphylococcus aureus prosthetic valve endocarditis: Optimal management and risk factors for death.
Clin Infect Dis, 26 (1998), pp. 1302-1309
[144.]
J.W. Chien, M.L. Kucia, R.A. Salata.
Use of linezolid, an oxazolidinone, in the treatment of multidrug-resistant gram-positive bacterial infections.
Clin Infect Dis, 30 (2000), pp. 146-151
[145.]
V. Ravindran, J. John, G.C. Kaye, R.E. Meigh.
Successful use of oral linezolid as a single active agent in endocarditis unresponsive to conventional antibiotic therapy.
J Infect, 47 (2003), pp. 164-166
[146.]
J.L. Mainardi, L. Gutmann, J.F. Acar, F.W. Goldstein.
Synergistic effect of amoxicillin and cefotaxime against Enterococcus faecalis.
Antimicrob Agents Chemother, 39 (1995), pp. 1984-1987
[147.]
L. Olaison, K. Schadewitz.
Enterococcal endocarditis in Sweden, 1995-1999: Can shorter therapy with aminoglycosides be used?.
Clin Infect Dis, 34 (2002), pp. 159-166
[148.]
J. Gavaldá, J.M. Miró, C. Torres, J. De La Torre-Cisneros, P. Muñoz, C. Peña, et al.
Efficacy of ampicillin plus ceftriaxone or cefotaxime in the treatment of endocarditis due to enterococcus faecalis.
41st Interscience Conference on Antimicrobial Agents and Chemother,
[149.]
H.M. Babcock, D.J. Ritchie, E. Christiansen, R. Starlin, R. Little, S. Stanley.
Successful treatment of vancomycin-resistant Enterococcus endocarditis with oral linezolid.
Clin Infect Dis, 32 (2001), pp. 1373-1375
[150.]
R. Patel, M.S. Rouse, K.E. Piper, J.M. Steckelberg.
Linezolid therapy of vancomycin-resistant Enterococcus faecium experimental endocarditis.
Antimicrob Agents Chemother, 45 (2001), pp. 621-623
[151.]
M.D. Macia, C. Juan, A. Oliver, O. Hidalgo, J.L. Pérez.
Caracterización molecular de un brote por Enterococcus faecalis resistente a los glucopéptidos en una unidad de cuidados intensivos. Enferm Infecc.
Microbiol Clin, 23 (2005), pp. 460-463
[152.]
T.C. Horan, R.P. Gaynes, W.J. Martone, W.R. Jarvis, T.G. Emori.
CDC definitions of nosocomial surgical site infections, 1992: A modification of CDC definitions of surgical wound infections.
Am J Infect Control, 20 (1992), pp. 271-274
[153.]
M.J. DiNubile, B.A. Lipsky.
Complicated infections of skin and skin structures: When the infection is more than skin deep.
J Antimicrob Chemother, 53 (2004), pp. ii37-ii50
[154.]
D.L. Stevens, A.L. Bisno, H.F. Chambers, E.D. Everett, P. Dellinger, E.J. Goldstein, et al.
Practice guidelines for the diagnosis and management of skin and soft-tissue infections.
Clin Infect Dis, 41 (2005), pp. 1373-1406
[155.]
D.R. Graham, C. Lucasti, O. Malafaia, R.L. Nichols, P. Holtom, N.Q. Pérez, et al.
Ertapenem once daily versus piperacillin-tazobactam 4 times per day for treatment of complicated skin and skin-structure infections in adults: Results of a prospective, randomized, doubleblind multicenter study.
Clin Infect Dis, 34 (2002), pp. 1460-1468
[156.]
R.L. Nichols, D.R. Graham, S.L. Barriere, A. Rodgers, S.E. Wilson, M. Zervos, et al.
Treatment of hospitalized patients with complicated gram-positive skin and skin structure infections: Two randomized, multicentre studies of quinupristin/dalfopristin versus cefazolin, oxacillin or vancomycin. Synercid Skin and Skin Structure Infection Group.
J Antimicrob Chemother, 44 (1999), pp. 263-273
[157.]
D.L. Stevens.
Teicoplanin for skin and soft tissue infections: An open study and a randomized, comparative trial versus cefazolin.
J Infect Chemother, 5 (1999), pp. 40-45
[158.]
D.L. Stevens, L.G. Smith, J.B. Bruss, M.A. McConnell-Martin, S.E. Duvall, W.M. Todd, et al.
Randomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections.
Antimicrob Agents Chemother, 44 (2000), pp. 3408-3413
[159.]
R.D. Arbeit, D. Maki, F.P. Tally, E. Campanaro, B.I. Eisenstein.
The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections.
Clin Infect Dis, 38 (2004), pp. 1673-1681
[160.]
J. Breedt, J. Teras, J. Gardovskis, F.J. Maritz, T. Vaasna, D.P. Ross, et al.
Safety and efficacy of tigecycline in treatment of skin and skin structure infections: Results of a double-blind phase 3 comparison study with vancomycin-aztreonam.
Antimicrob Agents Chemother, 49 (2005), pp. 4658-4666
[161.]
R.L. Nichols, J.W. Smith, R.W. Geckler, S.E. Wilson.
Meropenem versus imipenem/cilastatin in the treatment of hospitalized patients with skin and soft tissue infections.
South Med J, 88 (1995), pp. 397-404
[162.]
D.R. Graham, D.A. Talan, R.L. Nichols, C. Lucasti, M. Corrado, N. Morgan, et al.
Once-daily, high-dose levofloxacin versus ticarcillin-clavulanate alone or followed by amoxicillin-clavulanate for complicated skin and skin-structure infections: A randomized, open-label trial.
Clin Infect Dis, 35 (2002), pp. 381-389
[163.]
M.L. Grayson, M. McDonald, K. Gibson, E. Athan, W.J. Munckhof, P. Paull, et al.
Once-daily intravenous cefazolin plus oral probenecid is equivalent to once-daily intravenous ceftriaxone plus oral placebo for the treatment of moderate-to-severe cellulitis in adults.
Clin Infect Dis, 34 (2002), pp. 1440-1448
[164.]
M.E. Stryjewski, W.D. O’Riordan, W.K. Lau, F.D. Pien, L.M. Dunbar, M. Vallee, et al.
Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria.
Clin Infect Dis, 40 (2005), pp. 1601-1607
[165.]
E. Seltzer, M.B. Dorr, B.P. Goldstein, M. Perry, J.A. Dowell, T. Henkel.
Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections.
Clin Infect Dis, 37 (2003), pp. 1298-1303
[166.]
J. Weigelt, K. Itani, D. Stevens, W. Lau, M. Dryden, C. Knirsch.
Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections.
Antimicrob Agents Chemother, 49 (2005), pp. 2260-2266
[167.]
J. Weigelt, H.M. Kaafarani, K.M. Itani, R.N. Swanson.
Linezolid eradicates MRSA better than vancomycin from surgical-site infections.
Am J Surg, 188 (2004), pp. 760-766
[168.]
H.B. Fung, J.Y. Chang, S. Kuczynski.
A practical guide to the treatment of complicated skin and soft tissue infections.
Drugs, 63 (2003), pp. 1459-1480
[169.]
A.L. Bisno, D.L. Stevens.
Streptococcal infections of skin and soft tissues.
N Engl J Med, 334 (1996), pp. 240-245
[170.]
D.L. Stevens.
Dilemmas in the treatment of invasive Streptococcus pyogenes infections.
Clin Infect Dis, 37 (2003), pp. 341-343
[171.]
J. Zimbelman, A. Palmer, J. Todd.
Improved outcome of clindamycin compared with beta-lactam antibiotic treatment for invasive Streptococcus pyogenes infection.
Pediatr Infect Dis J, 18 (1999), pp. 1096-1100
[172.]
Z.D. Mulla, P.E. Leaverton, S.T. Wiersma.
Invasive group A streptococcal infections in Florida.
South Med J, 96 (2003), pp. 968-973
[173.]
S.R. Walsh, M.J. Ferraro, M.L. Durand.
Clindamycin-resistant Streptococcus pyogenes: Report of a case. Diagn.
Microbiol Infect Dis, 49 (2004), pp. 223-225
Copyright © 2007. Sociedad Española de Farmacia Hospitalaria
